77° weather-cloudy
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

262.96 -1.78 (-0.67%)
Streaming Delayed Price Updated: 10:12 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
News headline image
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
From Johnson & Johnson
Via Business Wire
News headline image
Could Buying This Dividend Pharma Stock Today Set You Up for Life? ↗
This Dividend King drug maker's dividend yield is roughly twice that of the S&P 500 index. 
Via The Motley Fool
Topics Stocks
Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value
Via Investor Brand Network
Topics Artificial Intelligence
Johnson & Johnson (NYSE:JNJ) Stands Out as a Quality Dividend Stock for Reliable Income ↗
Via Chartmill
News headline image
The Teleflex Pivot: Inside the $1 Billion Share Buyback and Strategic Breakup
Disclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories... 
Via Finterra
Topics Economy World Trade
News headline image
ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue
Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall... 
Via Finterra
Topics Economy World Trade
News headline image
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
JNJ (NYSE: JNJ) to release Q1 earnings before bell on April 14. Analysts expect $2.67/share & $23.6B revenue. FDA approves TECNIS PureSee lens. 
Via Benzinga
News headline image
Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value
From AINewsWire
Via GlobeNewswire
News headline image
These 3 Beaten-Down Stocks Haven't Been This Cheap in Over a Decade ↗
Buying stocks at incredibly low valuations often comes with risk, but it may also result in massive returns. 
Via The Motley Fool
Topics Economy World Trade
News headline image
This Healthcare Stock Has No Debt and a Near-Monopoly in Its Market ↗
The company is a picture of financial stability. 
Via The Motley Fool
News headline image
Martin Capital Dumps $4.5 Million in Robert Half Shares After a Brutal Year for the Staffing Sector ↗
Robert Half provides staffing and consulting services to global clients across accounting, finance, IT, legal, and creative sectors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
From Johnson & Johnson
Via Business Wire
News headline image
You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗
Could this player be heading into a new era of growth? 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System
ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"
ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that... 
Via MarketMinute
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded... 
Via MarketMinute
Topics Economy World Trade
News headline image
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,... 
Via MarketMinute
News headline image
Better Healthcare Stock to Own in a Recession: Defensive or Growth? ↗
The answer to the question might surprise many investors. It pays to be open-minded about risk. 
Via The Motley Fool
Topics Economy Energy
News headline image
JEPI vs. JEPQ: Which Is the Better Buy in April? ↗
These two high-yield heavyweights offer very different approaches. 
Via The Motley Fool
Topics Bonds ETFs Economy
News headline image
Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?
Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now. 
Via Barchart.com
News headline image
Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability
The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided... 
Via MarketMinute
Topics Economy Retirement
News headline image
This Healthcare Stock Barely Flinches During Market Sell-Offs ↗
Shares of Johnson & Johnson have fallen by less than 2% over the past month, while the S&P 500 has fallen by more than 7%. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Stagflation Fears Are Back: These 3 Stocks Can Help You Ride Out the Storm ↗
These blue-chip stocks can make investors money if stagflation returns -- and also if it doesn't. 
Via The Motley Fool
Topics Economy
News headline image
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
Volatility Is Spiking. Here Are 3 Dividend Stocks You Can Buy Without Hesitation. ↗
These dividend stocks are ones you can rest peacefully at night owning. 
Via The Motley Fool
Topics Economy
News headline image
The Dividend King That's Raised Its Payout for 63 Consecutive Years ↗
This healthcare leader can weather almost any storm. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Deep Dive: Boston Scientific (BSX) and the New Era of Medical Device Dominance
Date: March 31, 2026 Introduction Boston Scientific Corporation (NYSE: BSX) finds itself at a critical crossroads this morning. After a year of record-breaking growth and the successful launch of its... 
Via Finterra
Topics Lawsuit Product Recall
News headline image
1 Reason Eli Lilly Stock Is Still a Buy ↗
Eli Lilly is much more than just a weight loss stock. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is Intuitive Surgical a Buy Right Now? ↗
The healthcare leader has seen better times. 
Via The Motley Fool
Topics World Trade
News headline image
2 Stocks I Plan to Hold for the Next 20 Years ↗
These companies help me sleep peacefully at night. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.